SEC Form 4 · accession 0001178670-26-000048
ALNYLAM PHARMACEUTICALS, INC. · ALNY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David E I Pyott
Director
Period of report
Jun 1, 2026
Accepted (ET)
Jun 3, 2026 · 4:25 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001178670
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 1, 2026 | M | 3,830 | $0.00 | A | 5,412 | D | |
| Common StockF2 | Jun 1, 2026 | S | 921 | $297.71 | D | 4,491 | D | |
| Common StockF3 | Jun 1, 2026 | S | 1,175 | $298.91 | D | 3,316 | D | |
| Common StockF4 | Jun 1, 2026 | S | 1,222 | $299.87 | D | 2,094 | D | |
| Common StockF5 | Jun 1, 2026 | S | 495 | $300.72 | D | 1,599 | D | |
| Common Stock | Jun 1, 2026 | S | 17 | $302.65 | D | 1,582 | D | |
| Common StockF6 | holding | — | — | — | 27,900 | I | by Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F7 | $70.20 | Jun 1, 2026 | M | 3,830 | D | Jun 3, 2017 | Jun 3, 2026 | Common Stock | 3,830 | 0 | D |
Explanation of responses
- F1The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on November 12, 2025. The options exercised by the reporting person were due to expire on June 3, 2026.
- F2The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $297.31 to $297.99. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F3The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $298.33 to $299.33. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F4The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $299.36 to $300.19. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F5The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $300.45 to $301.15. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F6The shares of ALNY common stock were purchased by the David E I Pyott Trust, of which the reporting person is trustee.
- F7This stock option was fully vested and exercisable as of June 3, 2017.